Raptor Pharmaceutical Corp. Sets New 1-Year High at $15.39 (RPTP)
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) set a new 52-week high during mid-day trading on Friday, Analyst RN reports. The stock traded as high as $15.39 and last traded at $15.03, with a volume of 2,863,619 shares. The stock had previously closed at $14.51.
A number of analysts have recently weighed in on RPTP shares. Analysts at Ladenburg Thalmann raised their price target on shares of Raptor Pharmaceutical Corp. from $12.00 to $15.50 in a research note to investors on Monday, November 11th. They now have a “buy” rating on the stock. Separately, analysts at Janney Montgomery Scott raised their price target on shares of Raptor Pharmaceutical Corp. from $13.00 to $17.00 in a research note to investors on Monday, November 11th. They now have a “buy” rating on the stock. Finally, analysts at FBR & Co. initiated coverage on shares of Raptor Pharmaceutical Corp. in a research note to investors on Wednesday, October 30th. They set an “outperform” rating on the stock. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $14.93.
In other Raptor Pharmaceutical Corp. news, Director Llew Keltner sold 10,000 shares of Raptor Pharmaceutical Corp. stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $13.25, for a total transaction of $132,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Raptor Pharmaceutical Corp. has a 52 week low of $4.71 and a 52 week high of $15.29. The stock’s 50-day moving average is $13.64 and its 200-day moving average is $12.7. The company’s market cap is $901.6 million.
Raptor Pharmaceuticals Corp. (NASDAQ:RPTP), formerly TorreyPines Therapeutics, Inc, is an early development-stage Company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.